This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Research roundup: July 2026
What changed this month in GLP-1 and peptide evidence, pricing and regulation — and what it means.
This month
Three things moved. Brand pricing completed a collapse that began in late 2025, putting FDA-approved oral GLP-1s at $149/month. The FDA proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list closed its comment period on June 29. And the compounded market continued its pivot to "microdose" and ODT formats - neither of which has trial evidence behind it.
Pricing
The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of July 12, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
| Provider | Total / month | Billing | Dose | Notes |
|---|---|---|---|---|
| LillyDirect Foundayo (brand, oral) | $149/mo | Manufacturer direct | Oral / pill | 0.8mg starter, Self Pay Journey Program. CHEAPEST verified path to an FDA-approved oral GLP-1 for weight loss. Verified |
| NovoCare Pharmacy Wegovy (brand) | $149/mo | Manufacturer direct | Oral / pill | Wegovy TABLETS, 1.5mg and 4mg. Cheapest verified path to FDA-approved ORAL semaglutide for weight loss. Verified |
| LillyDirect Foundayo (brand, oral) | $199/mo | Manufacturer direct | Oral / pill | 2.5mg — step-up dose between starter and maintenance. Verified |
| Found Foundayo (brand, oral) | $248/mo | $149 med + $99 membership | Oral / pill | $149 med (0.8mg starter) + $99 CORE membership on 12-month plan. Escalates by dose. Verified |
| Shed Foundayo (brand, oral) | $274/mo | $149 med + $125 membership | Oral / pill | $149 med (starter) + $125 membership. Fulfilled via LillyDirect. Escalates $149->$199->$299 by dose tier. Verified |
| Shed Wegovy (brand) | $274/mo | $149 med + $125 membership | Oral / pill | Wegovy pill $149-$299 by dose + $125 membership (required for brand). Verified |
| Found Wegovy (brand) | $297/mo | $198 med + $99 membership | Oral / pill | $198 Wegovy pill + $99 CORE membership on 12-month plan. Verified |
| Hims Foundayo (brand, oral) | $298/mo | $149 med + $149 membership | Oral / pill | $149 med (0.8mg starter) + $149 membership ($39 first month). Higher doses cost more. Verified |
| Hers Foundayo (brand, oral) | $298/mo | $149 med + $149 membership | Oral / pill | $149 med (starter) + $149 membership ($39 first month). Higher doses cost more. Verified |
| Hims Wegovy (brand) | $298/mo | $149 med + $149 membership | Oral / pill | $149 Wegovy pill + $149 membership ($39 first month). Same price at all doses. Verified |
| Hers Wegovy (brand) | $298/mo | $149 med + $149 membership | Oral / pill | $149 Wegovy pill + $149 membership ($39 first month). Verified |
| LillyDirect Foundayo (brand, oral) | $299/mo | Manufacturer direct | Oral / pill | 5.5mg and 9mg — mid maintenance dose. Verified |
| LillyDirect Zepbound (brand) | $299/mo | Manufacturer direct | Injectable | 2.5mg starter, Self Pay Journey Program. 5mg $399; 7.5-15mg $449. Verified |
| PlushCare Zepbound (brand) | $319/mo | $299 med + $20 membership | Injectable | $299 Zepbound 2.5mg vial + $19.99 membership. 5mg $399; 7.5mg+ $449. Cheapest membership in the category. Verified |
| WeightWatchers Clinic Wegovy (brand) | $323/mo | $249 med + $74 membership | Injectable | $249 med (12-month supply PAID UPFRONT, $2,988) + $74/mo WW Med+ membership. Verified |
| Shed Wegovy (brand) | $324/mo | $199 med + $125 membership | Injectable | Wegovy PEN from $199 (higher doses more) + $125 membership. Prior $149 reflected the pill, not the pen. Verified |
| Found Wegovy (brand) | $347/mo | $248 med + $99 membership | Injectable | $248 Wegovy pen + $99 CORE membership on 12-month plan. Verified |
| Ro Foundayo (brand, oral) | $348/mo | $199 med + $149 membership | Oral / pill | $199 med + $149 Ro Body membership. Ongoing $199-$299 by dose. First month medication $149. Verified |
| Hims Wegovy (brand) | $348/mo | $199 med + $149 membership | Injectable | $199 Wegovy pen + $149 membership ($39 first month). Same price at all doses. Verified |
| Hers Wegovy (brand) | $348/mo | $199 med + $149 membership | Injectable | $199 Wegovy pen + $149 membership ($39 first month). Verified |
| Ro Wegovy (brand) | $348/mo | $199 med + $149 membership | Oral / pill | $199 med + $149 Ro Body membership. Annual prepay saves $50/mo; $74 membership on the annual plan. Verified |
| Ro Wegovy (brand) | $348/mo | $199 med + $149 membership | Injectable | $199-$399 med by dose + $149 Ro Body membership. Annual prepay saves $150/mo on medication. Verified |
| Hims Ozempic (brand) | $348/mo | $199 med + $149 membership | Injectable | $199 med + $149 membership. FDA-approved for T2D; off-label for weight loss only when clinically appropriate. Verified |
| Hers Ozempic (brand) | $348/mo | $199 med + $149 membership | Injectable | $199 med starter + $149 membership ($39 first month). FDA-approved for T2D. Verified |
| LillyDirect Foundayo (brand, oral) | $349/mo | Manufacturer direct | Oral / pill | 14.5mg and 17.2mg standard rate. DROPS to $299 with a refill within 45 days of previous delivery — its own 45-day rule, parallel to Zepbound's. Verified |
| NovoCare Pharmacy Wegovy (brand) | $349/mo | Manufacturer direct | Injectable | Month 3 onward, all maintenance doses. Cut from $499 in November 2025. Verified |
| NovoCare Pharmacy Ozempic (brand) | $349/mo | Manufacturer direct | Injectable | 0.25-1mg ongoing; $499 for the 2mg dose. FDA-approved for T2D. Verified |
| PlushCare Wegovy (brand) | $419/mo | $399 med + $20 membership | Injectable | $399 med + $19.99 membership (first month free). $129 initial visit billed separately. Verified |
| WeightWatchers Clinic Wegovy (brand) | $423/mo | $349 med + $74 membership | Injectable | $349 med + $74 WW Med+ membership ($25 first month). 12-month commitment available at $249/mo. Verified |
| Found Zepbound (brand) | $447/mo | $348 med + $99 membership | Injectable | $348 Zepbound KwikPen + $99 CORE membership on 12-month plan. Verified |
| Hims Zepbound (brand) | $448/mo | $299 med + $149 membership | Injectable | $299 Zepbound KwikPen + $149 membership ($39 first month). Higher doses cost more. Verified |
| Hers Zepbound (brand) | $448/mo | $299 med + $149 membership | Injectable | $299 Zepbound 2.5mg single-dose VIAL + $149 membership. Passes through Lilly's vial pricing: $299/$399/$449; refill within 45 days to hold the rate. NOTE: the pre-filled KwikPen is NOT in Lilly's vial-only self-pay programme, so a KwikPen price from Hers is UNCONFIRMED — verify at checkout. Verified |
| LillyDirect Zepbound (brand) | $449/mo | Manufacturer direct | Injectable | 7.5mg-15mg. MUST refill within 45 days of the previous delivery or the price rises. Verified |
| Shed Zepbound (brand) | $474/mo | $349 med + $125 membership | Injectable | $349 med ($349-$499 by dose) + $125 membership (required for brand). Was $299. Verified |
| Ro Zepbound (brand) | $548/mo | $399 med + $149 membership | Injectable | $399-$449 med by dose + $149 Ro Body membership. First month medication $299. Verified |
| PlushCare Ozempic (brand) | $1020/mo | $1,000 med + $20 membership | Injectable | RETAIL-LEVEL (~$1,000 med + $20 membership). NovoCare's direct programme is $349-$499 for the same drug. Verified |
| PlushCare Mounjaro (brand) | $1120/mo | $1,100 med + $20 membership | Injectable | RETAIL (~$1,100 med + $20 membership). Lilly runs NO Mounjaro self-pay programme. Zepbound is the same molecule at $299-$449. Verified |
| Found Ozempic (brand) | $1199/mo | $1,100 med + $99 membership | Injectable | RETAIL-LEVEL ($1,100 med + $99 membership). NovoCare sells it direct for $349. Verified |
| Found Mounjaro (brand) | $1199/mo | $1,100 med + $99 membership | Injectable | RETAIL ($1,100 med + $99 membership). Zepbound is the identical molecule at $299-$449 via LillyDirect. Verified |
| Eden Zepbound (brand) | $1498/mo | $1,399 med + $99 membership | Injectable | RETAIL-LEVEL. $1,399 med + $99 membership. LillyDirect sells the identical drug for $299-$449. Verified |
| Eden Wegovy (brand) | $1794/mo | $1,695 med + $99 membership | Injectable | RETAIL-LEVEL. $1,695 med + $99 membership. NovoCare sells the identical drug direct for $149-$349. Verified |
| Hers Mounjaro (brand) | $2048/mo | $1,899 med + $149 membership | Injectable | RETAIL ($1,899 med + $149 membership). No manufacturer self-pay programme exists for Mounjaro. Verified |
Regulatory
| Date | What happened | Why it matters |
|---|---|---|
| March 2022 | Semaglutide (Wegovy) added to the FDA drug shortage list. | Shortage begins — the legal window for compounding opens. |
| August 2022 | Ozempic (semaglutide) added to the shortage list. | |
| December 15, 2022 | Tirzepatide (Mounjaro, Zepbound) added to the shortage list. | Compounded tirzepatide becomes lawful under the shortage exception. |
| October 2, 2024 | FDA declares the tirzepatide shortage resolved. | The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close. |
| December 19, 2024 | FDA reaffirms the tirzepatide resolution in a declaratory order. | Sets a 60-day (503A) / 90-day (503B) transition. |
| February 18, 2025 | 503A enforcement discretion for tirzepatide ENDS. | State-licensed pharmacies must stop compounding tirzepatide copies. |
| February 21, 2025 | FDA removes semaglutide from the shortage list. | |
| March 19, 2025 | 503B enforcement discretion for tirzepatide ENDS. | Outsourcing facilities must stop compounding tirzepatide copies. |
| April 22, 2025 | 503A enforcement discretion for semaglutide ENDS. | |
| April 24, 2025 | Court denies the Outsourcing Facilities Association's injunction (semaglutide). | OFA v. FDA, N.D. Tex. — FDA's determination stands. |
| May 7, 2025 | Court upholds FDA on tirzepatide in OFA v. FDA. | The shortage-exception route is closed for both molecules. |
| May 22, 2025 | 503B enforcement discretion for semaglutide ENDS. | All shortage-based compounding of both molecules is now outside enforcement discretion. |
| April 30, 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. | Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period closed June 29, 2026. |
Evidence
No new registrational trial published this month. The most recent significant publication remains SURMOUNT-5 (NEJM, May 2025), the only head-to-head trial of tirzepatide against semaglutide.
| Trial | Arm | Result | Duration | Comparator | Source |
|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15 mg | −20.9% | 72 weeks | Placebo −3.1% | NEJM 2022 (Jastreboff et al.) |
| SURMOUNT-1 | Tirzepatide 10 mg | −19.5% | 72 weeks | NEJM 2022 | |
| SURMOUNT-1 | Tirzepatide 5 mg | −15.0% | 72 weeks | NEJM 2022 | |
| SURMOUNT-5 | Tirzepatide (max tolerated) | −20.2% | 72 weeks | vs semaglutide −13.7% | NEJM 2025 (Aronne et al.) |
| STEP 1 | Semaglutide 2.4 mg | −14.9% | 68 weeks | Placebo −2.4% | NEJM 2021 (Wilding et al.) |
| STEP 8 | Semaglutide 2.4 mg | −15.8% | 68 weeks | vs liraglutide 3.0 mg −6.4% | JAMA 2022 (Rubino et al.) |
| SCALE | Liraglutide 3.0 mg | −8.0% | 56 weeks | Placebo −2.6% | NEJM 2015 |
| SELECT | Semaglutide 2.4 mg | 20% MACE reduction | ~40 months | Cardiovascular outcomes | NEJM 2023 |
The gap between the evidence and the marketWorth restating, because it is the most-abused fact in this field: every one of those trials tested an FDA-approved subcutaneous injection. None tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet — the three things the telehealth market is now overwhelmingly selling.
What to watch
- The 503B bulks-list decision. If finalised, it closes the outsourcing-facility route entirely.
- Foundayo dose-escalation pricing. An approved oral GLP-1 at $149 changes the calculus for a lot of patients — but only if the escalated price ($199 to $349) stays competitive.
- Any pharmacokinetic data on compounded ODT. There is none today. If a provider publishes some, it would be the first real evidence in that category.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.